CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

Open access

Abstract

(1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibroblast growth factor 21 (FGF21) may improve NASH by modulating lipid and glucose metabolism. We compared effects of single drug to combination treatment as therapeutic strategies against NASH. (2) Methods: We analyzed serum samples and liver biopsies from 85 nonalcoholic fatty liver disease (NAFLD) patients. A CCR2/5 inhibitor (BMS-687681-02-020) and a pegylated FGF21 agonist (BMS-986171) were tested in male C57BL/6J mice subjected to dietary models of NASH and fibrosis (choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) up to 12 weeks; short- (2w) or long-term (6w) treatment). (3) Results: In NAFLD patients, chemokine CCL2 and FGF21 serum levels correlated with inflammatory serum markers, only CCL2 was significantly associated with advanced liver fibrosis. In rodent NASH, CCR2/5 inhibition significantly reduced circulating Ly6C+ monocytes and hepatic monocyte-derived macrophages, alongside reduced hepatic inflammation and fibrosis. FGF21 agonism decreased body weight, liver triglycerides and histological NASH activity. Combination treatment reflected aspects of both compounds upon short- and long-term application, thereby amplifying beneficial effects on all aspects of steatohepatitis and fibrosis. (4) Conclusions: CCR2/5 inhibition blocks hepatic infiltration of inflammatory monocytes, FGF21 agonism improves obesity-related metabolic disorders. Combined therapy ameliorates steatohepatitis and fibrosis more potently than single drug treatment in rodent NASH, corroborating the therapeutic potential of combining these two approaches in NASH patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23126696

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Correlation of CCL2 and FGF21 serum levels with severity of human NAFLD. Serum samples were obtained from patients with biopsy-proven NAFLD (n = 85). (A,B) CCL2 and FGF-21 serum levels measured by ELISA and correlated with histologically assessed severity of liver fibrosis and steatohepatitis. (C,D) Correlation of CCL2 serum concentrations with biomarkers of fibrosis (FIB-4 and GGT) and FGF-21 serum levels. (E) Association of FGF-21 serum levels with biomarkers of steatohepatitis (CK-18 fragment M30, GGT and AST). ns = non-significant, *** p < 0.001 (unpaired Student t test in (A,B) Spearman’s r and p-values of linear correlation analysis in (C–E)).
Figure 1 Correlation of CCL2 and FGF21 serum levels with severity of human NAFLD. Serum samples were obtained from patients with biopsy-proven NAFLD (n = 85). (A,B) CCL2 and FGF-21 serum levels measured by ELISA and correlated with histologically assessed severity of liver fibrosis and steatohepatitis. (C,D) Correlation of CCL2 serum concentrations with biomarkers of fibrosis (FIB-4 and GGT) and FGF-21 serum levels. (E) Association of FGF-21 serum levels with biomarkers of steatohepatitis (CK-18 fragment M30, GGT and AST). ns = non-significant, *** p < 0.001 (unpaired Student t test in (A,B) Spearman’s r and p-values of linear correlation analysis in (C–E)).CC BY · PubMed Central
Figure 2 Combination therapy by dual CCR2/CCR5 inhibition and FGF21 agonism ameliorates steatohepatitis and fibrosis more effectively than single drug treatment. (A) Pharmacologic treatment with CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v) was conducted over the last 6 weeks of 12 weeks CDAHFD (choline-deficient, amino acid-defined high-fat diet) administration to induce steatohepatitis and fibrosis. (B) Line graph of bodyweight development of all treatment groups (ctrl: control diet; Vhc: vehicle). (C) Representative H&E, Sirius Red and F4/80 immunohistochemistry staining (×10 magnification; scale bars = 100 µm. (D–F) Assessment of liver injury by serum alanine transaminase levels (ALT), of liver fibrosis by quantification of Sirius Red area fraction and hydroxyproline content and of hepatic triglyceride content. (G) Single parameters of the histopathological NAFLD activity score (NAS). (H–J) Quantification of flow cytometry for Ly6C+ blood monocytes, hepatic monocyte-derived macrophages (MoMF) and Kupffer cells (KC) and quantification of F4/80 positive area fraction. All data are presented as mean SD (n ≥ 6 per group), ns = non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001 (one-way ANOVA with post-hoc testing).
Figure 2 Combination therapy by dual CCR2/CCR5 inhibition and FGF21 agonism ameliorates steatohepatitis and fibrosis more effectively than single drug treatment. (A) Pharmacologic treatment with CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v) was conducted over the last 6 weeks of 12 weeks CDAHFD (choline-deficient, amino acid-defined high-fat diet) administration to induce steatohepatitis and fibrosis. (B) Line graph of bodyweight development of all treatment groups (ctrl: control diet; Vhc: vehicle). (C) Representative H&E, Sirius Red and F4/80 immunohistochemistry staining (×10 magnification; scale bars = 100 µm. (D–F) Assessment of liver injury by serum alanine transaminase levels (ALT), of liver fibrosis by quantification of Sirius Red area fraction and hydroxyproline content and of hepatic triglyceride content. (G) Single parameters of the histopathological NAFLD activity score (NAS). (H–J) Quantification of flow cytometry for Ly6C+ blood monocytes, hepatic monocyte-derived macrophages (MoMF) and Kupffer cells (KC) and quantification of F4/80 positive area fraction. All data are presented as mean SD (n ≥ 6 per group), ns = non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001 (one-way ANOVA with post-hoc testing).CC BY · PubMed Central
Figure 3 Blocking hepatic infiltration of monocytes and macrophages by CCR2/CCR5 inhibition in acute liver injury. (A) Acute liver injury was induced by a single CCl4 injection. Mice (n = 4 per group) received vehicle (Vhc), CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v). Liver injury and immune cell migration was assessed 36 h after injury induction. (B) H&E and F4/80 immunohistochemistry staining of representative liver sections of control and treatments groups (×10 magnification; scale bars = 100 µm). (C,D) Quantification of F4/80 positive area fraction. Hepatic injury was assessed by necrotic area fraction and serum alanine (ALT) and aspartate (AST) transaminase levels. (E–G) Representative flow cytometric plots of blood (MO = monocytes; Granulo = granulocytes) and liver (MO = monocytes; MoMF = monocyte-derived macrophages; KC = Kupffer cells) immune cell populations and corresponding quantification. Data are presented as mean ± SD (n = 6–8 per group), ns = non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001 (one-way ANOVA with post-hoc testing).
Figure 3 Blocking hepatic infiltration of monocytes and macrophages by CCR2/CCR5 inhibition in acute liver injury. (A) Acute liver injury was induced by a single CCl4 injection. Mice (n = 4 per group) received vehicle (Vhc), CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v). Liver injury and immune cell migration was assessed 36 h after injury induction. (B) H&E and F4/80 immunohistochemistry staining of representative liver sections of control and treatments groups (×10 magnification; scale bars = 100 µm). (C,D) Quantification of F4/80 positive area fraction. Hepatic injury was assessed by necrotic area fraction and serum alanine (ALT) and aspartate (AST) transaminase levels. (E–G) Representative flow cytometric plots of blood (MO = monocytes; Granulo = granulocytes) and liver (MO = monocytes; MoMF = monocyte-derived macrophages; KC = Kupffer cells) immune cell populations and corresponding quantification. Data are presented as mean ± SD (n = 6–8 per group), ns = non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001 (one-way ANOVA with post-hoc testing).CC BY · PubMed Central
Figure 4 Beneficial effects of combination therapy after short term treatment. (A) Steatohepatitis and fibrosis were induced by CDAHFD (choline-deficient, amino acid-defined high-fat diet) over a total period of 8 weeks. Effects of pharmacologic treatment were assessed after administration of CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v) over the last two weeks of injury induction. (B) Representative liver section of H&E, Sirius Red and F4/80 immunohistochemistry staining (×10 magnification; scale bars = 100 µm). (C,D) Serum alanine transaminase (ALT) levels, NAFLD activity score, hepatic triglyceride and hydroxyproline content as well as quantification of Sirius Red area fraction display the liver phenotype. (E,F) Quantification of F4/80 positive area fraction and flow cytometrically determined monocyte-derived macrophages (MoMFs) and liver Kupffer cells (KC). All data are presented as mean SD (n ≥ 6 per group) ns = non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001 (one-way ANOVA with post-hoc testing).
Figure 4 Beneficial effects of combination therapy after short term treatment. (A) Steatohepatitis and fibrosis were induced by CDAHFD (choline-deficient, amino acid-defined high-fat diet) over a total period of 8 weeks. Effects of pharmacologic treatment were assessed after administration of CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v) over the last two weeks of injury induction. (B) Representative liver section of H&E, Sirius Red and F4/80 immunohistochemistry staining (×10 magnification; scale bars = 100 µm). (C,D) Serum alanine transaminase (ALT) levels, NAFLD activity score, hepatic triglyceride and hydroxyproline content as well as quantification of Sirius Red area fraction display the liver phenotype. (E,F) Quantification of F4/80 positive area fraction and flow cytometrically determined monocyte-derived macrophages (MoMFs) and liver Kupffer cells (KC). All data are presented as mean SD (n ≥ 6 per group) ns = non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001 (one-way ANOVA with post-hoc testing).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 2

  1. Abdelmalek, M.F.A.S., Nakajima, A., Neuschwander-Tetri, B.A., Goodman, Z.D., Lawitz, E.J., Harrison, S.A., Jacobson, I.M., Imajo, K., Gunn, N., and Halegoua-DeMarzio, D. (2021, January 12–15). Efficacy and safety of pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis: Results from the phase 2b, randomized, double-blind, placebo-controlled FALCON 2 study. Proceedings of the American Association for the Study of Liver Diseases, The Liver Meeting, Virtual Conference.
  2. Sanyal, A.J.A.N., Neuschwander-Tetri, B.A., Goodman, Z., Harrison, S.A., Lawitz, E.J., Gunn, N., Imajo, K., Ravendhran, N., Akahane, T., and Boone, B. (2021, January 12–15). Efficacy and safety of pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis: Results from the phase 2b, randomized, double-blind, placebo-controlled FALCON 1 study. Proceedings of the American Association for the Study of Liver Diseases, The Liver Meeting, Virtual Conference.

Cited by

See all 59

Metadata

Authors
Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., Boehm, S., Zhao, Q., Krupinski, J., Charles, E. D., Zinker, B., & Tacke, F.
Affiliations
  • Universitätsklinikum Aachen (DE)
  • Ghent University (BE)
  • Charité – Universitätsmedizin Berlin (DE)
  • Department of Endocrinology, Ghent University, B-9000 Ghent, Belgium
  • Ghent University Hospital (BE)
  • Bristol-Myers Squibb (United States) (US)
Corresponding author
  • Puengel, Tobias
  • Lefere, Sander
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-06-15
Volume
23
Issue
12
Pages
6696
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4282967424
Cited by
59
References
49
Citations by year
2026: 8 · 2025: 12 · 2024: 17 · 2023: 19 · 2022: 3
FWCI
9.20
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (publishedVersion, other-oa)
  • RWTH Publications (RWTH Aachen)
Funders
German Research Foundation (403224013)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
Keywords
nonalcoholic steatohepatitis, liver fibrosis, FGF21 analogues, combination therapy, monocyte infiltration, hepatic macrophages, liver inflammation, choline-deficient L-amino acid-defined diet, high-fat diet, non-alcoholic fatty liver disease
MeSH terms
Animals, Disease Models, Animal, Fibroblast Growth Factors, Fibrosis, Humans, Liver, Liver Cirrhosis, Male, Mice, Inbred C57BL, Receptors, CCR5, Mice, Receptors, CCR2, Diet, High-Fat, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. https://app.cochat.ai/papers/10.3390/ijms23126696
The paper
Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., Boehm, S., Zhao, Q., Krupinski, J., Charles, E. D., Zinker, B., & Tacke, F. (2022). Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23126696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.